Cargando…
Persistent COVID-19 Pneumonia and Failure to Develop Anti-SARS-CoV-2 Antibodies During Rituximab Maintenance Therapy for Follicular Lymphoma
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier Inc.
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7442568/ https://www.ncbi.nlm.nih.gov/pubmed/32933879 http://dx.doi.org/10.1016/j.clml.2020.08.017 |
| _version_ | 1783573482616913920 |
|---|---|
| author | Yasuda, Hajime Tsukune, Yutaka Watanabe, Naoki Sugimoto, Kazuya Uchimura, Ayana Tateyama, Misa Miyashita, Yosuke Ochi, Yusuke Komatsu, Norio |
| author_facet | Yasuda, Hajime Tsukune, Yutaka Watanabe, Naoki Sugimoto, Kazuya Uchimura, Ayana Tateyama, Misa Miyashita, Yosuke Ochi, Yusuke Komatsu, Norio |
| author_sort | Yasuda, Hajime |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7442568 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | Elsevier Inc. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-74425682020-08-24 Persistent COVID-19 Pneumonia and Failure to Develop Anti-SARS-CoV-2 Antibodies During Rituximab Maintenance Therapy for Follicular Lymphoma Yasuda, Hajime Tsukune, Yutaka Watanabe, Naoki Sugimoto, Kazuya Uchimura, Ayana Tateyama, Misa Miyashita, Yosuke Ochi, Yusuke Komatsu, Norio Clin Lymphoma Myeloma Leuk Case Report Elsevier Inc. 2020-11 2020-08-22 /pmc/articles/PMC7442568/ /pubmed/32933879 http://dx.doi.org/10.1016/j.clml.2020.08.017 Text en © 2020 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Case Report Yasuda, Hajime Tsukune, Yutaka Watanabe, Naoki Sugimoto, Kazuya Uchimura, Ayana Tateyama, Misa Miyashita, Yosuke Ochi, Yusuke Komatsu, Norio Persistent COVID-19 Pneumonia and Failure to Develop Anti-SARS-CoV-2 Antibodies During Rituximab Maintenance Therapy for Follicular Lymphoma |
| title | Persistent COVID-19 Pneumonia and Failure to Develop Anti-SARS-CoV-2 Antibodies During Rituximab Maintenance Therapy for Follicular Lymphoma |
| title_full | Persistent COVID-19 Pneumonia and Failure to Develop Anti-SARS-CoV-2 Antibodies During Rituximab Maintenance Therapy for Follicular Lymphoma |
| title_fullStr | Persistent COVID-19 Pneumonia and Failure to Develop Anti-SARS-CoV-2 Antibodies During Rituximab Maintenance Therapy for Follicular Lymphoma |
| title_full_unstemmed | Persistent COVID-19 Pneumonia and Failure to Develop Anti-SARS-CoV-2 Antibodies During Rituximab Maintenance Therapy for Follicular Lymphoma |
| title_short | Persistent COVID-19 Pneumonia and Failure to Develop Anti-SARS-CoV-2 Antibodies During Rituximab Maintenance Therapy for Follicular Lymphoma |
| title_sort | persistent covid-19 pneumonia and failure to develop anti-sars-cov-2 antibodies during rituximab maintenance therapy for follicular lymphoma |
| topic | Case Report |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7442568/ https://www.ncbi.nlm.nih.gov/pubmed/32933879 http://dx.doi.org/10.1016/j.clml.2020.08.017 |
| work_keys_str_mv | AT yasudahajime persistentcovid19pneumoniaandfailuretodevelopantisarscov2antibodiesduringrituximabmaintenancetherapyforfollicularlymphoma AT tsukuneyutaka persistentcovid19pneumoniaandfailuretodevelopantisarscov2antibodiesduringrituximabmaintenancetherapyforfollicularlymphoma AT watanabenaoki persistentcovid19pneumoniaandfailuretodevelopantisarscov2antibodiesduringrituximabmaintenancetherapyforfollicularlymphoma AT sugimotokazuya persistentcovid19pneumoniaandfailuretodevelopantisarscov2antibodiesduringrituximabmaintenancetherapyforfollicularlymphoma AT uchimuraayana persistentcovid19pneumoniaandfailuretodevelopantisarscov2antibodiesduringrituximabmaintenancetherapyforfollicularlymphoma AT tateyamamisa persistentcovid19pneumoniaandfailuretodevelopantisarscov2antibodiesduringrituximabmaintenancetherapyforfollicularlymphoma AT miyashitayosuke persistentcovid19pneumoniaandfailuretodevelopantisarscov2antibodiesduringrituximabmaintenancetherapyforfollicularlymphoma AT ochiyusuke persistentcovid19pneumoniaandfailuretodevelopantisarscov2antibodiesduringrituximabmaintenancetherapyforfollicularlymphoma AT komatsunorio persistentcovid19pneumoniaandfailuretodevelopantisarscov2antibodiesduringrituximabmaintenancetherapyforfollicularlymphoma |